ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

Adalimumab & Infliximab Remain in Newborns after Delivery

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2016

A recent study showed that, when administered during pregnancy, infliximab takes longer to clear an infant’s system than adalimumab…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabAnti-TNFinflammatory bowel diseaseinfliximabpregnancy

How to Deliver Difficult News about Patients' Diagnoses

How to Deliver Difficult News about Patients’ Diagnoses

Karen Appold  |  July 14, 2015

Telling a patient that he or she has been diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis, fibromyalgia or another debilitating, painful and/or chronic condition can be upsetting for a patient to hear and difficult for a rheumatologist to convey. Given this, it’s important to prepare for the appointment. “Take a few minutes beforehand to contemplate…

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:chronic conditionDiagnosispatient carephysicianrheumatologist

Prior Authorization Requests Delay or Prevent Delivery of Needed Meds

Richard Quinn  |  March 27, 2015

Rheumatologist denounces common practice as a time-draining impediment to patient care

Filed under:Practice Support Tagged with:Health InsuranceMedicationpatient carePractice Managementprior authorizationrheumatologist

Nanoparticle Medicine Delivery Shows Promise

Kurt Ullman  |  June 13, 2013

Researchers treated mouse model of systemic lupus erythematous with mycophenolic acid delivered via nanoparticle. (posted June 18, 2013)

Filed under:Drug Updates Tagged with:LupusNanoparticleSLE

Electronic Prescribing: The First Step Towards an Integrated Health Delivery System?

Staff  |  February 1, 2009

With the introduction of the 2009 Centers for Medicare and Medicaid Services’ (CMS’s) electronic prescribing incentive program, the door is opening for widespread adoption of health information technology (HIT) within the physician’s practice.

Filed under:From the CollegePractice Support Tagged with:Practice Tips

Reflections on B Cells in SLE & Lupus Nephritis

Ruth Jessen Hickman, MD  |  October 30, 2025

At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.

Filed under:ACR ConvergenceMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNLupusLupus nephritissystemic lupus erythematosus (SLE)

Dr. Tait Shanafelt, with ACR President Dr. Carol Langford

Burnout Requires Attention, Advocacy for Research & More

Vanessa Caceres  |  October 30, 2025

This year’s Opening Session of ACR Convergence 2025 featured a well-known thought leader on physician burnout, Dr. Tait Shanafelt, who provided insight into the risk of burnout and how to prevent it. Key leadership also addressed research advocacy and more.

Filed under:ACR ConvergenceCareerMeeting ReportsProfessional TopicsWorkforce Tagged with:ACR Convergence 2025

The Role of FGL-1 in Sjögren Disease

Arthritis & Rheumatology  |  October 29, 2025

Fibrinogen-like protein-1 (FGL-1) may play a key role in the onset of autoimmunity by suppressing T cell activation in primary Sjögren disease, according to findings from Otsuka et al. Their study, which examined the influence of interorgan communication on disease pathogenesis in mice models and patients with primary Sjögren disease, may help facilitate novel diagnostic or therapeutic strategies targeting immune checkpoint molecules in autoimmune diseases.

Filed under:ConditionsSjögren’s Disease Tagged with:Fibrinogen-like protein-1 (FGL-1)liver

Updates on Fibromyalgia & the Quest to Alleviate Pain

Jason Liebowitz, MD, FACR  |  October 29, 2025

ACR Convergence 2025 speakers reviewed new fibromyalgia insights, from the first new drug approval since 2009 to nociplastic pain concepts & cognitive behavioral therapy.

Filed under:ACR ConvergenceAnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:ACR Convergence 2025Chronic paincognitive behavioral therapyFibromyalgianociplastic painPainSleepsuzetrigine

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Filed under:ACR ConvergenceMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNdrugInflammatory Brain DiseasesInflammatory MyopathiesLupusLupus nephritisRheumatic Diseasesystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 128
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences